Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
Autore:
Petropoulos, CJ; Parkin, NT; Limoli, KL; Lie, YS; Wrin, T; Huang, W; Tian, H; Smith, D; Winslow, GA; Capon, DJ; Whitcomb, JM;
Indirizzi:
ViroLog Inc, S San Francisco, CA 94080 USA ViroLog Inc S San Francisco CAUSA 94080 c, S San Francisco, CA 94080 USA
Titolo Testata:
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
fascicolo: 4, volume: 44, anno: 2000,
pagine: 920 - 928
SICI:
0066-4804(200004)44:4<920:ANPDSA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIV-INFECTED PATIENTS; PROTEASE INHIBITOR THERAPY; REVERSE-TRANSCRIPTASE GENE; HIGH-LEVEL RESISTANCE; ANTIRETROVIRAL THERAPY; IN-VIVO; ZIDOVUDINE RESISTANCE; COMBINATION THERAPY; VARIANTS; MUTATION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
69
Recensione:
Indirizzi per estratti:
Indirizzo: Petropoulos, CJ 270 E Grand Ave, S San Francisco, CA 94080 USA 270 E Grand Ave S San Francisco CA USA 94080 CA 94080 USA
Citazione:
C.J. Petropoulos et al., "A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1", ANTIM AG CH, 44(4), 2000, pp. 920-928

Abstract

Although combination antiretroviral therapy has resulted in a considerableimprovement in the treatment of human immunodeficiency virus (HIV) type 1 (HIV-1) infection, the emergence of resistant virus is a significant obstacle to the effective management of HIV infection and AIDS. We have developeda novel phenotypic drug susceptibility assay that may be useful in guidingtherapy and improving long-term suppression of HIV replication. Susceptibility to protease (PR) and reverse transcriptase (RT) inhibitors is measuredby using resistance test vectors (RTVs) that contain a luciferase indicator gene and PR and RT sequences derived from HIV-1 in patient plasma. Cells are transfected with RTV DNA, resulting in the production of virus particles that are used to infect target cells. Since RTVs are replication defective, luciferase activity is measured following a single round of replication. The assay has been automated to increase throughput and is completed in 8 to 10 days. Test results may be useful in facilitating the selection of optimal treatment regimens for patients who have failed prior therapy or drug-naive patients infected with drug-resistant virus. In addition, the assay can be used to evaluate candidate drugs and assist in the development of newdrugs that are active against resistant strains of HIV-1.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/10/20 alle ore 00:21:09